Role of biological agents in treatment of rheumatoid arthritis - ScienceDirect
Targeted Delivery Platforms for the Treatment of Multiple Sclerosis | Molecular Pharmaceutics
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay | Science Translational Medicine
Frontiers | Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies
Safety of biologic therapy in rheumatoid arthritis | Nature Reviews Rheumatology
U.S. International Trade Commission will investigate AbbVie claims that rival stole secrets - STAT
Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients | PLOS ONE
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet
Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When? - European Medical Journal
Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When? - European Medical Journal
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis | Neurology Neuroimmunology & Neuroinflammation
Topical nanocarriers for management of Rheumatoid Arthritis: A review - ScienceDirect
Unresolved issues in biologic therapy for rheumatoid arthritis | Nature Reviews Rheumatology
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases
Biologicals in rheumatoid arthritis: current and future | RMD Open
Nocebos in rheumatology: emerging concepts and their implications for clinical practice | Nature Reviews Rheumatology
Generic drugmakers Teva and Sandoz make major push to biosimilars | Reuters
About TRUXIMA® (rituximab-abbs) | Rheumatoid Arthritis | See Safety Info
Biosimilar Prices: How Much They Cost and How to Save - GoodRx
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial | Annals of the Rheumatic Diseases
Biomedicines | Free Full-Text | Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
